Safety of Apollo Micro Catheter in Pediatric Patients
Safety of Apollo Embolization Delivery Micro Catheter in Pediatric Patients With Vascular Malformations
This is a clinical trial/study for patients diagnosed with brain arteriovenous malformation
(AVM). An AVM is an abnormal connection between the arteries and veins of the brain. Patients
considered for this trial are 21 years and younger with AVM suitable for embolization
treatment (a procedure used to block the abnormal connection between the arteries and veins
of the brain) with Onyx Liquid Embolic System (Onyx LES) or TruFill n-Butyl Cyanoacrylate
(n-BCA) Liquid Embolic System (both are liquid substances used in the embolization procedure
to block the abnormal connection).
-Why is this study being done?
The purpose of this study is to evaluate the safety of the Apollo Embolization Delivery Micro
Catheter device (device that looks like a long thin hallow tube) when used in Pediatric
patients with vascular malformations.
The Apollo Onyx Delivery Micro Catheter device is manufactured by Micro Therapeutics, Inc.
d/b/a ev3 Neurovascular. Apollo Onyx™ Delivery Micro Catheter device is not approved for use
in the U.S, although it is widely used and approved for use in Europe (CE0297).
This clinical study is sponsored by Dr. Alejandro Berenstein of St.Luke's-Roosevelt Hospital,
New York who is also the principal Investigator of the study. Total duration of study is up
to 30 months with approximately an 18 months enrollment period. Patients follow up period is
up to 12 months upon enrollment.
The study's primary endpoint is the incidence of catheter entrapment.
Incidence of unintentional catheter tip detachment.
Brain Arteriovenous Malformation
Apollo Micro Catheter device
Study Arms / Comparison Groups
Description: Apollo Micro catheter device
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
- The subject or subject's legally authorized representative has signed and dated an
informed Consent Form.
- Subject's age is ≤ 21 years.
- The subject has a confirmed diagnosis of brain arteriovenous malformation in the
cerebral cortex, cerebellum or dura mater that is indicated for endovascular
embolization with Onyx™ LES or TruFill n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic
Systems and where the use of Apollo Embolization Delivery Micro Catheter may or may
not be indicated for surgical resection.
- The subject is clinically and neurologically stable for a minimum of 48 hours prior to
- The subject has a life expectancy of at least 1 year with the exception of new born
babies with Vein of Galen malformation with cardiopulmonary failure where no other
treatment option remains.
- The subject agrees to and is capable of completing all study required procedures
- Female who is pregnant or lactating.
- Current participation in another investigational drug or device study.
- Subject has a brain tumor or other malignancy
N/A - 21 Years
Accepts Healthy Volunteers
Ahmed Otokiti, MBBS, ,
St. Luke's-Roosevelt Hospital Center
Ahmed Otokiti, MBBS, Study Director, St. Luke's-Roosevelt Hospital Center